Healthcare resource and lost labour costs of migraine headache in the US.

abstract：:Rufinamide (Inovelon®), a triazole derivative, is an oral antiepileptic drug approved in the EU as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients aged ≥4 years. The efficacy of oral rufinamide as adjunctive therapy in patients with LGS uncontrolled on one to t...

journal_title：PharmacoEconomics

authors： McCormack PL

更新日期：2012-03-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes. DESIGN AND SETTING:A Markov process model was constructed to model the effectiveness, as measured by time without depression, ...

journal_title：PharmacoEconomics

authors： Nuijten M,Hadjadjeba L,Evans C,van den Berg J

更新日期：1998-10-01 00:00:00

abstract：:Over the last decade, there has been a proliferation in the number of economic evaluations of pharmaceuticals to meet the growing demand for information about the economic benefits of healthcare technologies. The majority of these studies have been commissioned by pharmaceutical companies for the purposes of drawing a...

journal_title：PharmacoEconomics

authors： Pang F

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the communi...

journal_title：PharmacoEconomics

authors： Vale L,Steffens H,Donaldson C

更新日期：2004-01-01 00:00:00

abstract：:Constipation is one of the most common digestive complaints. It is a symptom, not a disease. The subjectivity that this involves means that assessments of clinical epidemiology, socioeconomic costs and pharmacotherapy are difficult, since there is no definition of 'normal' bowel habit. Although constipation can affect...

journal_title：PharmacoEconomics

authors： Passmore AP

更新日期：1995-01-01 00:00:00

abstract：:Decision makers increasingly request evidence on the real-world cost effectiveness of a new treatment. There is, however, a lack of practical guidance on how to conduct an economic evaluation based on registry data and how this evidence can be used in actual decision making. This paper explains the required steps on h...

journal_title：PharmacoEconomics

authors： Blommestein HM,Franken MG,Uyl-de Groot CA

更新日期：2015-06-01 00:00:00

abstract：:Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

journal_title：PharmacoEconomics

authors： Arguedas MR,Eloubeidi MA

更新日期：2001-01-01 00:00:00

abstract：:The aim of this prospective sequential multinational (5 countries) study was to concurrently evaluate the effects of subcutaneous sumatriptan on clinical parameters, health-related quality-of-life (HRQOL) measures, workplace productivity and patient satisfaction. This report presents the HRQOL results. 582 patients (a...

journal_title：PharmacoEconomics

authors： Dahlöf C,Bouchard J,Cortelli P,Heywood J,Jansen JP,Pham S,Hirsch J,Adams J,Miller DW

更新日期：1997-01-01 00:00:00

abstract：BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...

journal_title：PharmacoEconomics

authors： Meads DM,Marshall A,Hulme CT,Dunn JA,Ford HE

更新日期：2016-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to assess the cost effectiveness of using epoetin-alpha (erythropoietin) to augment preoperative autologous donation (PAD) of blood prior to elective cardiac surgery. DESIGN AND SETTING:We designed a decision-analytic model incorporating the risk of receiving allogeneic blood,...

journal_title：PharmacoEconomics

authors： Coyle D,Lee KM,Fergusson DA,Laupacis A

更新日期：2000-08-01 00:00:00

abstract：:Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

journal_title：PharmacoEconomics

authors： Cohen BJ

更新日期：2003-01-01 00:00:00

abstract：CONTEXT:This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required. METHODS:A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nomi...

journal_title：PharmacoEconomics

authors： Rogowski W,Payne K,Schnell-Inderst P,Manca A,Rochau U,Jahn B,Alagoz O,Leidl R,Siebert U

更新日期：2015-01-01 00:00:00

abstract：OBJECTIVE:To evaluate the effect of using different cost-effectiveness measures in the economic evaluation of cholesterol-modifying pharmacotherapy. DESIGN AND SETTING:An economic model was used to examine the extent to which the relative cost effectiveness of cholesterol-modifying agents varies depending upon the cos...

journal_title：PharmacoEconomics

authors： Morris S,Godber E

更新日期：1999-08-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic ...

journal_title：PharmacoEconomics

authors： Grutters JP,Sculpher M,Briggs AH,Severens JL,Candel MJ,Stahl JE,De Ruysscher D,Boer A,Ramaekers BL,Joore MA

更新日期：2013-02-01 00:00:00

abstract：OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

journal_title：PharmacoEconomics

authors： Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

更新日期：2019-12-01 00:00:00

abstract：:Given the policy relevance and growing volume of research measuring individuals' willingness to pay (WTP) for health-related goods and services, meta-analysis provides a potentially rich set of tools for answering key questions about this research area. In particular, when taken as a whole, what does the existing empi...

journal_title：PharmacoEconomics

authors： Van Houtven G

更新日期：2008-01-01 00:00:00

abstract：AIM:To assess the relative cost effectiveness of escitalopram compared with venlafaxine XR in patients with major depressive disorder (MDD). METHODS:An economic evaluation was conducted alongside a double-blind, multinational, randomised clinical trial and examined the costs and quality of life of 251 patients taking ...

journal_title：PharmacoEconomics

authors： Fernandez JL,Montgomery S,Francois C

更新日期：2005-01-01 00:00:00

abstract：:Economic analysts are increasingly likely to rely on systematic reviews and meta-analyses of health state utility values to inform the parameter inputs of decision-analytic modelling-based economic evaluations. Beyond the context of economic evaluation, evidence from systematic reviews and meta-analyses of health stat...

journal_title：PharmacoEconomics

authors： Petrou S,Kwon J,Madan J

更新日期：2018-09-01 00:00:00

abstract：:The development of evidence to demonstrate 'value for money' is regarded as an important step in facilitating the search for the optimal allocation of limited resources and has become an essential component in healthcare decision making. Real-world evidence collected from de-identified individuals throughout the conti...

journal_title：PharmacoEconomics

authors： Kolasa K,Ken Redekop W,Berler A,Zah V,Asche CV

更新日期：2020-10-01 00:00:00

abstract：OBJECTIVE:The reliability and validity of generic utility measures have not yet been summarized in people with multiple sclerosis (MS). It is important to assess the psychometric properties of these measures, to ensure that the values obtained by the scoring system are valid for interpretation and utilization by clinic...

journal_title：PharmacoEconomics

authors： Kuspinar A,Mayo NE

更新日期：2014-08-01 00:00:00

abstract：:Discrete choice experiments (DCEs) are regularly used in health economics to elicit preferences for healthcare products and programmes. There is growing recognition that DCEs can provide more than information on preferences and, in particular, they have the potential to contribute more directly to outcome measurement ...

journal_title：PharmacoEconomics

authors： Lancsar E,Louviere J

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Health-related quality of life (HRQoL) is a key outcome in cost-utility analyses, which are commonly used to inform healthcare decisions. Different instruments exist to evaluate HRQoL, however while some jurisdictions have a preferred system, no gold standard exists. Standard meta-analysis struggles with the...

journal_title：PharmacoEconomics

authors： Schmitz S,Makovski TT,Adams R,van den Akker M,Stranges S,Zeegers MP

更新日期：2020-01-01 00:00:00

abstract：BACKGROUND:Within the framework of economic evaluations, the transferability of utility scores between jurisdictions remains unclear. The EQ-5D is a generic instrument for measuring health-related quality of life in economic evaluations, which can be used for comparing utility scores across countries. At present, the E...

journal_title：PharmacoEconomics

authors： Knies S,Evers SM,Candel MJ,Severens JL,Ament AJ

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:Our objective was to identify, among the information routinely collected on patients in intensive care units (ICUs), data that determine the total cost for a given patient. DESIGN:We developed a model that could help physicians in medical ICUs to estimate the cost of care for their patients when no cost data...

journal_title：PharmacoEconomics

authors： Chaix C,Durand-Zaleski I,Alberti C,Brun-Buisson C

更新日期：1999-06-01 00:00:00

abstract：:The objective of this study was to demonstrate the cost effectiveness of long term maintenance treatment with citalopram versus standard therapy (defined as short term antidepressant treatment) in patients with major depression in Germany. We chose doxepin, amitriptyline and trimipramine as standard therapy because th...

journal_title：PharmacoEconomics

authors： Nuijten MJ,Hardens M,Souêtre E

更新日期：1995-08-01 00:00:00

abstract：:This article explores the need to perform pharmacoeconomic evaluations of herbal medicines and assesses the extent to which this approach has been applied so far to these products. There seems to be no compelling need for pharmacoeconomic analyses of herbal over-the-counter medicines, but such analyses are certainly w...

journal_title：PharmacoEconomics

authors： De Smet PA,Bonsel G,Van der Kuy A,Hekster YA,Pronk MH,Brorens MJ,Lockefeer JH,Nuijten MJ

更新日期：2000-07-01 00:00:00

abstract：:The broad spectrum of antibacterial activity and favourable pharmacokinetic profile of ciprofloxacin permit oral treatment of many serious infections which have traditionally necessitated parenteral antibacterial therapy. This has been demonstrated in comparative studies, in which ciprofloxacin was as effective and w...

journal_title：PharmacoEconomics

authors： Balfour JA,Faulds D

更新日期：1993-05-01 00:00:00

abstract：OBJECTIVE:To estimate the economic value of pharmacological treatment of type 2 diabetes mellitus in overweight and obese patients using orlistat in addition to standard diabetes therapy (i.e., a sulphonlyurea, metformin or insulin) and weight management strategies as compared with standard diabetes therapy and weight ...

journal_title：PharmacoEconomics

authors： Maetzel A,Ruof J,Covington M,Wolf A

更新日期：2003-01-01 00:00:00

abstract：:Answering the demanding questions asked of pharmacotherapy in the 21st century will require more reliance on the disciplines of pharmacoepidemiology and pharmacoeconomics. Pharmacoepidemiology can help assess patterns and appropriateness of drug utilisation, provide explanations for poor compliance, quantify the frequ...

journal_title：PharmacoEconomics

authors： Avorn J

更新日期：2004-01-01 00:00:00

abstract：OBJECTIVE:To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam. Methods and perspective: A decision an...

journal_title：PharmacoEconomics

authors： Tavakoli M

更新日期：2003-01-01 00:00:00